Cargando…

Radiation therapy in the era of immune treatment for hepatocellular carcinoma

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment in recent years and provide new opportunities to treat hepatocellular carcinoma (HCC). To date, several ICIs have been approved by the FDA for advanced HCC in first-line or second-line therapy. Downstaging conversion therapy fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lingjuan, Zhang, Ruiguang, Lin, Zhenyu, Tan, Qiaoyun, Huang, Zhiyong, Liang, Binyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895775/
https://www.ncbi.nlm.nih.gov/pubmed/36742293
http://dx.doi.org/10.3389/fimmu.2023.1100079
_version_ 1784881915588771840
author Chen, Lingjuan
Zhang, Ruiguang
Lin, Zhenyu
Tan, Qiaoyun
Huang, Zhiyong
Liang, Binyong
author_facet Chen, Lingjuan
Zhang, Ruiguang
Lin, Zhenyu
Tan, Qiaoyun
Huang, Zhiyong
Liang, Binyong
author_sort Chen, Lingjuan
collection PubMed
description Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment in recent years and provide new opportunities to treat hepatocellular carcinoma (HCC). To date, several ICIs have been approved by the FDA for advanced HCC in first-line or second-line therapy. Downstaging conversion therapy for potentially resectable HCC to provide opportunities for surgical intervention is challenging. ICIs have become a hot spot in this field due to their high response rate. However, HCC has various etiologies and can evade the immune system through multiple mechanisms, which limit the efficacy of ICI monotherapy and demand novel combination strategies. Radiation therapy (RT) is also a candidate for conversion therapy in HCC and is currently gaining increasing attention as a good combination partner with ICIs due to its ability to modulate the tumor microenvironment. In this review, we illustrate the current indications for ICIs and RT in HCC, the rationale for their synergistic combination, and the current clinical trials in combination therapy. We also speculate on predictive biomarkers and novel future strategies to further enhance the efficacy of this combination. This review aims to provide references for future research on radiation and immunotherapy to arrive at a promising new era of HCC treatment.
format Online
Article
Text
id pubmed-9895775
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98957752023-02-04 Radiation therapy in the era of immune treatment for hepatocellular carcinoma Chen, Lingjuan Zhang, Ruiguang Lin, Zhenyu Tan, Qiaoyun Huang, Zhiyong Liang, Binyong Front Immunol Immunology Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment in recent years and provide new opportunities to treat hepatocellular carcinoma (HCC). To date, several ICIs have been approved by the FDA for advanced HCC in first-line or second-line therapy. Downstaging conversion therapy for potentially resectable HCC to provide opportunities for surgical intervention is challenging. ICIs have become a hot spot in this field due to their high response rate. However, HCC has various etiologies and can evade the immune system through multiple mechanisms, which limit the efficacy of ICI monotherapy and demand novel combination strategies. Radiation therapy (RT) is also a candidate for conversion therapy in HCC and is currently gaining increasing attention as a good combination partner with ICIs due to its ability to modulate the tumor microenvironment. In this review, we illustrate the current indications for ICIs and RT in HCC, the rationale for their synergistic combination, and the current clinical trials in combination therapy. We also speculate on predictive biomarkers and novel future strategies to further enhance the efficacy of this combination. This review aims to provide references for future research on radiation and immunotherapy to arrive at a promising new era of HCC treatment. Frontiers Media S.A. 2023-01-20 /pmc/articles/PMC9895775/ /pubmed/36742293 http://dx.doi.org/10.3389/fimmu.2023.1100079 Text en Copyright © 2023 Chen, Zhang, Lin, Tan, Huang and Liang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Chen, Lingjuan
Zhang, Ruiguang
Lin, Zhenyu
Tan, Qiaoyun
Huang, Zhiyong
Liang, Binyong
Radiation therapy in the era of immune treatment for hepatocellular carcinoma
title Radiation therapy in the era of immune treatment for hepatocellular carcinoma
title_full Radiation therapy in the era of immune treatment for hepatocellular carcinoma
title_fullStr Radiation therapy in the era of immune treatment for hepatocellular carcinoma
title_full_unstemmed Radiation therapy in the era of immune treatment for hepatocellular carcinoma
title_short Radiation therapy in the era of immune treatment for hepatocellular carcinoma
title_sort radiation therapy in the era of immune treatment for hepatocellular carcinoma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895775/
https://www.ncbi.nlm.nih.gov/pubmed/36742293
http://dx.doi.org/10.3389/fimmu.2023.1100079
work_keys_str_mv AT chenlingjuan radiationtherapyintheeraofimmunetreatmentforhepatocellularcarcinoma
AT zhangruiguang radiationtherapyintheeraofimmunetreatmentforhepatocellularcarcinoma
AT linzhenyu radiationtherapyintheeraofimmunetreatmentforhepatocellularcarcinoma
AT tanqiaoyun radiationtherapyintheeraofimmunetreatmentforhepatocellularcarcinoma
AT huangzhiyong radiationtherapyintheeraofimmunetreatmentforhepatocellularcarcinoma
AT liangbinyong radiationtherapyintheeraofimmunetreatmentforhepatocellularcarcinoma